Embryonics

Embryonics operates within the Health Tech and Life Sciences sector, focusing on fertility healthcare through the application of artificial intelligence. Founded in May 2018 by Yael Gold-Zamir, who also serves as President, and David Silver, the company's CTO, Embryonics aims to improve the success rates of in vitro fertilization (IVF) procedures. The company is headquartered in Tel Aviv, Israel, with a research and development center in Haifa.

The core of Embryonics' business is to transition IVF from a subjective practice to a data-driven science, thereby increasing success rates for fertility clinics and reducing expenses for patients. The company provides its services to fertility clinics, offering a suite of AI-powered software solutions. The business model is centered on leveraging big data and deep learning algorithms to analyze various aspects of the IVF process. The company secured $4 million in a Seed funding round in January 2021, with investors including Google for Startups, Innovation Authority, and others. In January 2023, Embryonics was acquired by Rhea, a platform for modern fertility services.

Embryonics has developed a platform that utilizes AI to address key challenges in IVF. One of its main products is an embryo selection tool that analyzes time-lapse videos of developing embryos to predict their implantation probability. This technology, named Ubar, employs geometric deep learning to identify embryonic features correlated with genetic health and successful implantation that are not visible to the human eye. The system provides a numerical score for each embryo, assisting clinicians in making more informed decisions. Beyond embryo selection, the company's AI extends to creating personalized hormonal treatment protocols and providing recommendations for egg preservation. The technology was developed using a dataset from tens of thousands of IVF cycles and has been presented in peer-reviewed studies. A key milestone was achieving a CE mark for its embryo selection product. Additionally, the company developed a HIPAA-compliant web application with an intuitive interface for doctors to visualize oocyte development and grade embryos, which helps to continually train the neural network.

Keywords: fertility healthcare, IVF, artificial intelligence, deep learning, embryo selection, Health Tech, genetic screening, hormonal protocol, reproductive technology, data-driven science, medical imaging, fertility clinics, CE marked, non-invasive genetic screening, personalized fertility treatment, oocyte selection, implantation probability, big data analytics, machine vision, algorithm development